SecBot SecBot
PRESS-RELEASE ·Filed Jun 11, 2026

TOVX

Theriva Biologics, Inc.
BULLISH
Impact 7/10
Horizonweeks Processed5mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight ▲ Bullish

The publication in a peer-reviewed journal and encouraging OS data (17.3 months in refractory HNSCC) could drive near-term speculative buying. However, the stock has historically reversed gains within 5 days on similar news. Monitor for partnership announcements or financing updates; the SYN-004 trial is stalled pending funding, which may cap upside.

DirectionBullish
Confidencemedium
Horizonweeks

How the stock moved after the report

BULLISH VIEWSTOCK BELOW ENTRY AT T+60
Entry
$0.3070
T+0 close · Jun 11, 2026 · via day close
Latest settled
−17.59%
T+60 · $0.2530
Vs SPY
−21.99%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 11 $0.3070entry
  2. T+1 · 5mo ago −1.04%α −1.58% · $0.3038
  3. T+5 · 5mo ago −12.05%α −12.49% · $0.2700
  4. T+20 · 4mo ago −23.62%α −25.51% · $0.2345
  5. T+60 · 2mo ago −17.59%α −21.99% · $0.2530
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

Theriva Biologics announced publication of Phase 1 trial results for VCN-01 in immunotherapy-refractory HNSCC in Clinical Cancer Research. The data showed median overall survival of up to 17.3 months in the high-dose sequential arm, with translational evidence of immune resensitization.

Key Facts

  • Phase 1 trial results published in Clinical Cancer Research for VCN-01 + durvalumab in immunotherapy-refractory metastatic HNSCC
  • Median overall survival: 10.3 months (Arm I LD), 15.5 months (Arm II LD), 17.3 months (Arm II HD)
  • Median progression-free survival: 1.6 months (Arm I LD), 3.7 months (Arm II LD), 2.1 months (Arm II HD)
  • Biomarker data showed increased PD-L1+ T-cells, CD8 upregulation, and reduced Treg markers consistent with immune reactivation
  • 20 patients enrolled across three arms; no new safety signals highlighted
  • SYN-004 (ribaxamase) HCT trial has completed 2 of 3 cohorts, with third cohort dependent on additional funding

Financial Impact

No financial data provided; pre-revenue clinical-stage company with $11M market cap. Positive Phase 1 data may support partnering or financing but no near-term revenue.

cash runwaypartnership potential

Risk Factors

  • Micro-cap biotech with $11M market cap, high volatility and liquidity risk
  • Phase 1 data is early; larger randomized trials needed for regulatory approval
  • SYN-004 HCT trial requires additional funding to complete third cohort

Market Snapshot

Exchange
NYSE
Sector
Pharmaceutical Preparations
Analyst Consensus
88% bullish (8 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3310376

Track record

11 reports on TOVX

Performance horizon

3 of 4 bullish or bearish reports moved the stock their way by T+1. Best: +17.39% at T+60 after the Aug 4, 2026 report. 3 of 4 went positive at some point.

Filters
  1. Nov 12, 20264d ago Press Release Neutral 4/10 Entry $0.1600 to $0.1441 Now $0.1400 −12.50% ▼ −9.94% −9.57% vs SPY
  2. Nov 2, 202614d ago 8-K Neutral 5/10 Entry $0.1820 to $0.1900 Now $0.1400 −23.08% ▲ +4.40% +2.74% vs SPY
  3. Oct 20, 202627d ago DEF 14A Bearish 5/10 Entry $0.1966 to $0.1900 Now $0.1400 +28.79% ▲ +3.36% +2.18% vs SPY
  4. Aug 11, 202613w ago 8-K Neutral 4/10 No price data
  5. Aug 11, 202613w ago Press Release Neutral 5/10 Entry $0.2300 to $0.2400 Now $0.1400 −39.13% ▲ +4.35% +4.10% vs SPY
  6. Aug 4, 202614w ago 8-K Bearish 4/10 Entry $0.2300 to $0.2251 Now $0.1400 +39.13% ▲ +2.13% +1.93% vs SPY
  7. Jul 7, 202618w ago 8-K Bullish 5/10 Entry $0.2354 to $0.2378 Now $0.1400 −40.53% ▲ +1.02% +1.33% vs SPY
  8. Jun 11, 202622w ago Press Release Bullish 7/10 Viewing Entry $0.3070 to $0.3038 Now $0.1400 −54.40% ▼ −1.04% −1.58% vs SPY
  9. Apr 17, 202630w ago 8-K Bullish 7/10 Entry $0.4100 to $0.3400 Now $0.1400 −65.85% ▼ −17.07% −16.42% vs SPY
  10. Mar 12, 202635w ago 8-K Mixed 6/10 Entry $0.1800 to $0.1800 Now $0.1400 −22.22% · 0.00% +0.60% vs SPY
Showing 10 of 11

US Market Status

Market Closed · Opens in 6h 1m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 11, 2026